The American journal of managed care
-
A database of information about more than 30,000 patients verified improved morbidity and mortality due to vaccines and preventive health care in prospective trials.
-
To identify areas where transition from hospital to community could be improved, with a special focus on racial, ethnic, and language differences. ⋯ Our findings highlight the enhanced difficulties that diverse patients may experience when transitioning from hospital to community-based settings. When considering how to best address the complex needs of diverse populations, interventions must be sensitive to the presence or absence of others, potential digital divides, and medical interpretation.
-
Observational Study
Association of physician specialty with psoriatic arthritis treatment and costs.
To describe current psoriatic arthritis treatment and costs by provider specialty using real-world claims data. ⋯ In patients with newly diagnosed psoriatic arthritis, physician specialty was associated with different medication choices but not costs.
-
As of May 2021, the United States remains the world leader with 33 million of 165 million cases worldwide (20%) and 590,000 of 3.4 million deaths worldwide (17%) from COVID-19. Achieving herd immunity by disease spread and vaccination may result in 2 million to 4 million total US deaths. The future perfect of the vaccine should not be the enemy of the present good, which is masking. ⋯ Any economic advantages of pandemic politics are short-lived and shortsighted in comparison with public health strategies of proven benefit that can prevent needless and mostly avoidable premature deaths from COVID-19. During the worst epidemic in more than 100 years, most Americans (75%) trust their health care providers. As competent and compassionate health care professionals, we recommend that effective strategies, especially masking, and not pandemic politics, should inform all rational clinical and public health decision-making.
-
Inflammatory bowel disease (IBD) is commonly associated with iron deficiency anemia (IDA), with a multifactorial pathophysiology. Diagnosis of both IDA and IBD places patients at risk for poor quality of life, as well as increased hospitalization and healthcare utilization. Treatment of IDA involves iron repletion with either oral or intravenous iron products. When selecting therapy, the total expenses of care must be considered, including direct and indirect costs, as well as patient clinical outcomes.